Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of rupatadine 10 mg in persistent allergic rhinitis
2004-001130-16Phase 4
- Sponsor
- Uriach
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of rupatadine in allergic rhinitis (AR), sponsored by Uriach. Primary endpoint: Percentage of serious adverse events.
02
Drugs
rupatadine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2004-001130-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001130-16.